Eli Lilly (NYSE: LLY) reported $65.18 billion in annual revenue for 2025, up 44.7% year over year. The growth was driven largely by its GLP-1 drugs Mounjaro and Zepbound, which together accounted for over a third of total sales.
Eli Lilly Revenue
Eli Lilly Annual Revenue
| Year | Revenue | YoY Change |
|---|---|---|
| 2025 | $65.18 B | +44.70% |
| 2024 | $45.04 B | +32.00% |
| 2023 | $34.12 B | +19.56% |
| 2022 | $28.54 B | +0.79% |
| 2021 | $28.31 B | +15.40% |
| 2020 | $24.53 B | +9.95% |
| 2019 | $22.31 B | +0.11% |
| 2018 | $22.29 B | -2.52% |
| 2017 | $22.87 B | +7.77% |
| 2016 | $21.22 B | +6.33% |
